Amyloid-β aggregation inhibitor, pharmaceutical composition foramyloid-β aggregation disease, and use application of same
A drug that inhibits aggregation of amyloid-β, which causes Alzheimer's disease and the like. The amyloid-βaggregation inhibitor is characterized by containing at least one of a peptide having an amino acid sequence of SEQ ID NO: 1 (GSGNR) or a peptide having an amino acid sequence of SEQ ID NO: 2 (GSGFK). A pharmaceutical composition for an amyloid-βaggregation disease is characterized by containing at least one of a peptide having an amino acid sequence of SEQ ID NO: 1 (GSGNR), and a peptide having an amino acid sequence of SEQ ID NO: 2 (GSGFK).
1 . A method for inhibiting aggregation of amyloid-β, comprising administering an amyloid-β aggregation inhibitor to a subject in need thereof,
wherein the amyloid-β aggregation inhibitor is a peptide selected from the group consisting of GSGNR (SEQ ID NO: 1) and GSGFK (SEQ ID NO: 2),
wherein the subject is a human or a non-human animal.
2 . A method for treating an amyloid-β aggregation disease caused by aggregation of amyloid-β, comprising administering an amyloid-β aggregation inhibitor to a subject in need thereof,
wherein the amyloid-β aggregation inhibitor is a peptide selected from the group consisting of GSGNR (SEQ ID NO: 1) and GSGFK (SEQ ID NO: 2).
3 . The method according to claim 1 , wherein the amyloid-β aggregation inhibitor is included in a pharmaceutical composition comprising the amyloid-β aggregation inhibitor and a pharmaceutically acceptable carrier.
4 . The method according to claim 1 , wherein the subject in need thereof is suffering from at least one disease selected from the group consisting of memory impairment, Alzheimer's disease, and cerebral amyloid angiopathy.
5 . The method according to claim 1 , wherein the amyloid-β aggregation inhibitor is administered to the subject prophylactically for an amyloid-β aggregation disease.
6 . The method according to claim 3 , wherein the pharmaceutical composition further comprises an active component that degrades amyloid-β aggregates that have been formed.
7 . The method according to claim 6 , wherein the active component that degrades amyloid-β aggregates that have been formed comprises a catalytic peptide that exhibits hydrolytic activity and degrades the amyloid-β aggregates through cleavage thereof.
8 . The method according to claim 2 , wherein the amyloid-β aggregation inhibitor is included in a pharmaceutical composition comprising the amyloid-β aggregation inhibitor and a pharmaceutically acceptable carrier.
9 . The method according to claim 2 , wherein the subject in need thereof is suffering from at least one disease selected from the group consisting of memory impairment, Alzheimer's disease, and cerebral amyloid angiopathy.
10 . The method according to claim 2 , wherein the amyloid-β aggregation inhibitor is administered to the subject prophylactically for an amyloid-β aggregation disease.
11 . The method according to claim 8 , wherein the pharmaceutical composition further comprises an active component that degrades amyloid-β aggregates that have been formed.
12 . The method according to claim 11 , wherein the active component that degrades amyloid-β aggregates that have been formed comprises a catalytic peptide that exhibits hydrolytic activity and degrades the amyloid-β aggregates through cleavage thereof.